MAAT INDEX

CLAIM #22987 · EMR (EMR) · 2026Q1 earnings call · Feb 3, 2026 · due Sep 30, 2026

We still expect to return approximately $2.2 billion to shareholders through $1.2 billion in dividends and $1 billion of share repurchase, of which we completed $250 million in Q1.

Michael Baughman · CFO

PENDING
graded after results covering Sep 30, 2026 are reported

How to check this claim

Look at: Total capital returned to shareholders via dividends paid plus share repurchases, fiscal year 2026

It came true if: Combined dividends and share repurchases >= $2.1 billion (approximately $2.2 billion, with dividends ~$1.2 billion and repurchases ~$1.0 billion)

Where: Company cash flow statement / capital allocation disclosures (10-K or Q4 2026 earnings release)

In context

ts year over year due to lower volume offset by benefits from price and cost reductions. Please turn to Slide 10, where I will bridge Q1 adjusted EPS from the prior year. Excluding the $0.06 impact of software renewals, operations delivered $0.10 of incremental EPS in Q1. Software and Systems contributed $0.08, reflecting strong operational execution, and Intelligent Devices added $0.02. Non-operating items added $0.04 from share count and tax rate benefits. Overall, adjusted EPS grew 6% year on year to $1.46. Please turn to Slide 11 for an overview of our Q2 and full-year 2026 guidance. We are reiterating our full-year guidance for sales, adjusted segment EBITDA margin, and free cash flow. We are raising the bottom and midpoint of our 2026 adjusted EPS guide and now expect $6.4 to $6.55. We still expect to return approximately $2.2 billion to shareholders through $1.2 billion in dividends and $1 billion of share repurchase, of which we completed $250 million in Q1. Turning to the second quarter, sales growth is expected to be 3% to 4% with underlying sales growth of 1% to 2%. We expect adjusted segment EBITDA margin of approximately 27% and adjusted EPS of $1.5 to $1.55. I will provide additional details on guidance in the following two slides. Please turn to Slide 12 for our 2026 group underlying sales guidance. We expect Software and Systems to be flat in Q2 and up 4% for the full year. Test and Measurement is planned to have high single-digit growth in both Q2 and the full year, while the Control Systems and Software segment is expected to be down low single digits in Q2 due to a $65 million headwind from the timing of software contract renewals. As a reminder, this accounting dynamic adversely affects GAAP revenues by $110 million in the first h

Verify independently

SEC filings for EMR · Claim quote is verbatim from the 2026Q1 earnings call.